

*Not for release, publication or distribution, directly or indirectly, in Australia, Canada, Japan or the United States.*

*These materials are not an offer for sale of securities in the United States. Securities may not be sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended (the “Securities Act”). Banca Farmafactoring S.p.A. does not intend to register any part of the offering in the United States or to conduct a public offering of Shares in the United States. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from Banca Farmafactoring S.p.A. and will contain detailed information about the company and management, as well as financial statements. Any securities sold in the United States will be sold only to qualified institutional buyers (as defined in Rule 144A under the Securities Act) pursuant to Rule 144A.*

*This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons in (i), (ii) and (iii) above together being referred to as “relevant persons”). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.*

*This document is an advertisement and is not a prospectus for the purposes of the Prospectus Directive. A prospectus prepared pursuant to the Prospectus Directive will be published. Investors should not subscribe for any securities referred to in this document except on the basis of information contained in the prospectus.*

*In any EEA Member State that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Directive. The expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in any relevant Member State) and includes any relevant implementing measure in the relevant Member State.*

## **PRESS RELEASE**

### **BFF BANKING GROUP**

#### **Mid- period stabilisation announcement**

Milan, 26 April 2017 – BFF Banking Group (MTA: BFF) – upon communication by Mediobanca-Banca di Credito Finanziario S.p.A., acting as the stabilisation agent in connection with the IPO of BFF shares on the MTA – communicates that Mediobanca has undertaken stabilisation transactions (as defined in Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) in relation to the offering of the following securities, as set out below.

#### **Securities:**

Issuer:	Banca Farmafactoring S.p.A.
Securities:	Ordinary shares (ISIN: IT0005244402)
Offering size:	53.000.000 ordinary shares excluding the over-allotment

	option
Offer price:	Euro 4,7 per ordinary share
Market:	Mercato Telematico Azionario, organized and managed by Borsa Italiana S.p.A.
Alphanumeric Code:	BFF
Stabilisation Manager:	Mediobanca – Banca di Credito Finanziario S.p.A. (telephone: +39 02 8829)

**Stabilisation Transactions executed on 13 April 2017:**

Aggregate number of ordinary shares purchased:	Number of transactions:	Price range (Euros):	Execution Venue:
90.000	28	4,10 – 4,294	Borsa Italiana – Mercato Telematico Azionario

**BFF Banking Group**

BFF Banking Group is the leading player in Europe in the management and nonrecourse factoring of receivables towards the Public Administrations. BFF Banking Group operates in Italy, Poland, Czech Republic, Slovakia, Spain and Portugal. In 2016 the Group's consolidated adjusted net profit was Euro 88 million and the CET1 ratio for the Banking Group at year end 2016 was 16.7%.

**Contacts**

**Media Relations - Barabino & Partners**

Sabrina Ragone                      Elena Bacis  
[s.ragone@barabino.it](mailto:s.ragone@barabino.it)      [e.bacis@barabino.it](mailto:e.bacis@barabino.it)  
T +39 02 72023535              T +39 02 72023535  
M +39 338 2519534              M +39 329 0742079

**IR, Strategy and Communication**

Laura Spotorno  
[laura.spotorno@bffgroup.com](mailto:laura.spotorno@bffgroup.com)  
T +39 02 49905.458  
M +39 338 5772272